Source-grounded facts extracted from Oncotelic Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Oncotelic Therapeutics, Inc. completed an acquisition involving Lunai Bioworks, Inc. for aggregate stated value of $20,000,000 (closed 2026-05-01).
“greement and Plan of Merger (the “Merger Agreement”) with Lunai Bioworks, Inc., a Delaware corporation (“Lunai”), Lunai Bioworks IP, Inc., a Delaware corporation and a wholly owned subsidiary of Lunai (“Merger Sub”), Neurobridge IP Holdings”
Oncotelic Therapeutics, Inc. entered into Asset Transfer Agreement with Autotelic Inc. (effective 2026-04-30).
“On April 30, 2026, the Company and Autotelic Inc. (“Autotelic”) entered into an asset transfer agreement (the “Asset Transfer Agreement”)”
Oncotelic Therapeutics, Inc. entered into Joint Development, Manufacturing, and Licensing Agreement with TechForce Robotics, Inc. valued at Joint development and manufacturing of AI-enabled, GMP-compliant robotic systems; non-exclusive lice (effective 2026-03-31).
“On March 31, 2026, Oncotelic Therapeutics, Inc. (the “Company”) entered into a Joint Development, Manufacturing, and Licensing Agreement (the “Agreement”) with TechForce Robotics, Inc. (“TechForce”), a Nevada corporation.”
Oncotelic Therapeutics, Inc. incurred convertible notes of $398,333.33 with Mast Hill Fund, LP at 10% per annum maturing the earlier of (a) the one-year anniversary of the date of the 2026 Mast Hill Purchase Agreement, or (b) the acceleration of the maturity...upon occurrence of a.
“On January 23, 2026, Oncotelic Therapeutics, Inc. (the "Company" or "Our") entered into a Securities Purchase Agreement (the "2026 Mast Hill Purchase Agreement "), with Mast Hill Fund, LP (" Mast Hill "), and the Company issued a convertible promissory note in the aggregate gross principal amount of $398,333.33 (the " 2026 Mast Hill Note ").”
Oncotelic Therapeutics, Inc. entered into 2026 Mast Hill Purchase Agreement with Mast Hill Fund, LP valued at $398,333.33 (effective 2026-01-23).
“On January 23, 2026, Oncotelic Therapeutics, Inc. (the “Company” or “Our”) entered into a Securities Purchase Agreement (the “2026 Mast Hill Purchase Agreement ”), with Mast Hill Fund, LP (“ Mast Hill ”), and the Company issued a convertible promissory note in the aggregate gross principal amount of $398,333.33 (the “ 2026 Mast Hill Note ”).”
Oncotelic Therapeutics, Inc. amended ICA with Jefferson Capital Ventures, LLC (effective 2025-12-31).
“On December 31, 2025, Oncotelic Therapeutics, Inc. (the “Company” or “Our”) entered into an amendment to an independent contractor agreements (“ICA”) with Jefferson Capital Ventures, LLC (“Jefferson”) dated August 6, 2025, for modifying the threshold of the first milestone contained within the ICA.”
Oncotelic Therapeutics, Inc. incurred convertible notes of $560,000 with Mast Hill Fund, LP at 10% per annum maturing earlier of (a) one-year anniversary of the date of the 2025 Mast Hill Purchase Agreement, or (b) acceleration by Mast Hill upon Event of Default, or (c) on prep.
“On July 31, 2025, Oncotelic Therapeutics, Inc. (the “Company” or “Our”) entered into a Securities Purchase Agreement (the “2025 Mast Hill Purchase Agreement ”), with Mast Hill Fund, LP (“ Mast Hill ”), and the Company issued a convertible promissory note in the aggregate gross principal amount of $560,000 (the “ 2025 Mast Hill Note ”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.